Strategic alliances can benefit SMEs as well as Big Pharma, says CRO DZS

By Dan Stanton contact

- Last updated on GMT

Strategic alliances can benefit SMEs as well as Big Pharma, says DZS

Related tags: Contract research organization, Merck serono

Strategic partnerships are “flexible, cost-effective and will become the trend over the next few years,” says CRO DZS, which has signed a multi-year deal with SBI Pharmaceuticals.

Parexel described strategic partnerships as “the next phase”​in relations between contract research organisations (CROs) and sponsors last year, and a glut of deals between pharma and CROs help to demonstrate the trend.

However, whilst the focus has been on contracts between Big Pharma and Big CROs - such as Merck Serono and Quintiles​, GSK and PPD​, and Pfizer with Parexel and ICON​ - strategic partnerships can also benefit small and mid-sized companies, according to Greg Ambra, VP of Clinical Operations at DZS Clinical Services.

“DZS is still a relatively small CRO and there are many sponsors who may be in search for more traditional, well-known CROs,”​ he told “However, because of our size, flexibility, core expertise, and broad range of eClinical services, we feel there is an unmet need in the small to mid-size pharma and biotech category that we can serve.”

The New Jersey-based company has just signed a multi-year and multi-project contract with SBI Pharmaceuticals, granting the Japan-based pharma firm access to all its services and software at preferred pricing globally, but with particular focus in the MENA region.

“We see a shift towards more ‘creative’ partnerships driven by both biopharm sponsors and CROs,”​ Ambra said. “We feel partnerships which create stability, have a risk-sharing element to them, are flexible, cost-effective and will become the trend over the next few years.”

SBI opted to partner with DZS rather than sign the CRO up under a straight-forward provider contract was due to a number of factors, according to Ambra.

“We have facilitated enrollment with creative solutions, and implemented cost efficiencies which SBI has appreciated,”​ he said. Furthermore, the CRO’s management team and steering committee, set-up to oversee activities, identify risks, and resolve issues quickly, “led to strong feeling of ‘partnership’ which eventually led to [the] agreement.”

Related news

Show more

Related products

show more

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 17-Jan-2022 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Planning Your Preclinical Assessment

Planning Your Preclinical Assessment

Altasciences | 17-Jan-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Related suppliers

Follow us


View more